Base de dados : MEDLINE
Pesquisa : E01.370.372.250.250.325 [Categoria DeCS]
Referências encontradas : 15186 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1519 ir para página                         

  1 / 15186 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29505541
[Au] Autor:Noh HM; Yoo JH; Jeong JY; Park YS
[Ad] Endereço:Department of Family Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang.
[Ti] Título:Bone mineral density after treatment for gastric cancer: Endoscopic treatment versus gastrectomy.
[So] Source:Medicine (Baltimore);97(1):e9582, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Changes in bone metabolism among gastric cancer survivors have long been recognized. The aim of our study was to clarify the changes of bone mineral density (BMD) among gastric cancer survivors who underwent endoscopic resection or gastrectomy. Forty-nine patients diagnosed with tumor, node, and metastasis (TNM) stage 1 gastric cancer with pathologic confirmation, who underwent BMD measurement just before the procedure, and had no prior osteoporosis treatment, were studied. BMD was measured with dual energy x-ray absorptiometry before and after treatment. Laboratory tests were performed using fresh serum, and serum levels of alkaline phosphatase, albumin, calcium, and phosphorus were measured. We used a nested case-control design to compare groups. Of the 49 patients, 34 underwent gastrectomy and 15 underwent endoscopic treatment. There were no differences in baseline clinical characteristics, including BMD, and biochemical data between groups. The mean and median follow-up intervals for BMD measurement were 32.6 months (standard deviation, 16.5) and 31.0 months (interquartile range: 21.5, 41.0), respectively. The follow-up BMDs of the femoral neck and total hip were lower in the gastrectomy group (P = .010 and .011, respectively). The percentage changes in BMD for the lumbar spine, femoral neck, and total hip were -3.30%, -1.52%, and 0.40%, respectively, in the endoscopic treatment group, and -7.17%, -6.30%, and -3.49%, respectively, in the gastrectomy group. Bone loss of the lumbar spine and femoral neck were greater in the gastrectomy group (P = .028 and .022, respectively). BMD is lower after gastrectomy than after endoscopic treatment among early stage gastric cancer survivors.
[Mh] Termos MeSH primário: Adenocarcinoma/cirurgia
Densidade Óssea
Gastrectomia
Gastroscopia
Neoplasias Gástricas/cirurgia
[Mh] Termos MeSH secundário: Adenocarcinoma/metabolismo
Adulto
Idoso
Osso e Ossos/metabolismo
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Neoplasias Gástricas/metabolismo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009582


  2 / 15186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29458667
[Au] Autor:Atrisco-Morales J; Martínez-Santos VI; Román-Román A; Alarcón-Millán J; De Sampedro-Reyes J; Cruz-Del Carmen I; Martínez-Carrillo DN; Fernández-Tilapa G
[Ad] Endereço:1​Laboratorio de Investigación Clínica, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Guerrero, Av. Lázaro Cárdenas s/n C.U. Sur. Chilpancingo, Guerrero, C.P. 39090, Mexico.
[Ti] Título:vacA s1m1 genotype and cagA EPIYA-ABC pattern are predominant among Helicobacter pylori strains isolated from Mexican patients with chronic gastritis.
[So] Source:J Med Microbiol;67(3):314-324, 2018 Mar.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Virulent genotypes of Helicobacter pylori vacA s1m1/cagA /babA2 have been associated with severe gastric diseases. VacA, CagA and BabA are polymorphic proteins, and their association with the disease is allele-dependent. The aims of this work were: (i) to determine the prevalence of H. pylori by type of chronic gastritis; (ii) to describe the frequency of cagA, babA2 and vacA genotypes in strains from patients with different types of chronic gastritis; (iii) to characterize the variable region of cagA alleles. METHODOLOGY: A total of 164 patients with chronic gastritis were studied. Altogether, 50 H. pylori strains were isolated, and the status of cagA, babA2 and vacA genotypes was examined by PCR. cagA EPIYA segment identification was performed using PCR and sequencing of cagA fragments of six randomly selected strains.Results/Key findings. The overall prevalence of H. pylori was 30.5 %. Eighty percent of the isolated strains were vacA s1m1, and the cagA and babA2 genes were detected in 74 and 32 % of the strains, respectively. The most frequent genotypes were vacA s1m1/cagA /babA2 and vacA s1m1/cagA /babA2 , with 40 % (20/50) and 28 % (14/50), respectively. In cagA , the most frequent EPIYA motif was -ABC (78.4 %), and EPIYA-ABCC and -ABCCC motifs were found in 10.8 % of the strains. A modified EPIYT-B motif was found in 66.6 % of the sequenced strains. CONCLUSION: H. pylori strains carrying vacA s1m1, cagA and babA2 genotypes were the most prevalent in patients with chronic gastritis from the south of Mexico. In the cagA strains, the EPIYA-ABC motif was the most common.
[Mh] Termos MeSH primário: Antígenos de Bactérias/genética
Proteínas de Bactérias/genética
Gastrite/microbiologia
Infecções por Helicobacter/microbiologia
Helicobacter pylori/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Alelos
Doença Crônica/epidemiologia
Feminino
Gastrite/epidemiologia
Gastroscopia
Genótipo
Helicobacter pylori/isolamento & purificação
Seres Humanos
Masculino
México/epidemiologia
Meia-Idade
Reação em Cadeia da Polimerase
Estômago/microbiologia
Estômago/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Bacterial); 0 (Bacterial Proteins); 0 (VacA protein, Helicobacter pylori); 0 (cagA protein, Helicobacter pylori)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180221
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000660


  3 / 15186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390275
[Au] Autor:Li J; Zhou C; Liu W; Sun X; Meng X
[Ad] Endereço:From the Department of Gastroenterology, First Hospital of Jilin University.
[Ti] Título:Synchronous diffuse large B-cell lymphoma of the stomach and small cell lung carcinoma: A case report.
[So] Source:Medicine (Baltimore);96(50):e8873, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: The synchronous occurrence of lung cancer in patients with gastric neoplasms is relatively uncommon, especially the cases of synchronous coexistence of small cell lung carcinoma and diffuse large B-cell lymphoma of the stomach. PATIENT CONCERNS: We encountered a case of synchronous primary small cell lung carcinoma and diffuse large B-cell lymphoma of the stomach. A 63-year-old patient with a 7.5 × 5.09 cm mass in the superior lobe of the right lung diagnosed with small cell lung cancer and synchronous diffuse large B-cell lymphoma of the stomach. DIAGNOSES: The diseases were diagnosed by the pathological biopsy and immunohistochemical methods. INTERVENTIONS: As the patient received CHOP chemotherapy, pulmonary function deterioraed. Etoposide was added to the chemotherapy. OUTCOMES: However, after the first treatment, chest computed tomography showed that the mass in the superior lobe of the right lung had increased to 8.5 × 5.2 cm. LESSONS: This report draws attention to the fact that the treatment of synchronous tumors is a challenge.
[Mh] Termos MeSH primário: Carcinoma de Células Pequenas/diagnóstico
Neoplasias Pulmonares/diagnóstico
Linfoma Difuso de Grandes Células B/diagnóstico
Neoplasias Primárias Múltiplas/diagnóstico
Neoplasias Gástricas/diagnóstico
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica
Biópsia
Carcinoma de Células Pequenas/tratamento farmacológico
Carcinoma de Células Pequenas/patologia
Ciclofosfamida
Doxorrubicina
Feminino
Gastroscopia
Seres Humanos
Imuno-Histoquímica
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias Pulmonares/patologia
Linfoma Difuso de Grandes Células B/tratamento farmacológico
Linfoma Difuso de Grandes Células B/patologia
Meia-Idade
Neoplasias Primárias Múltiplas/tratamento farmacológico
Neoplasias Primárias Múltiplas/patologia
Prednisona
Neoplasias Gástricas/tratamento farmacológico
Neoplasias Gástricas/patologia
Tomografia Computadorizada por Raios X
Vincristina
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
5J49Q6B70F (Vincristine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008873


  4 / 15186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328644
[Au] Autor:Grgov S; Tasic T; Radovanovic-Dinic B; Benedeto-Stojanov D
[Ti] Título:Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
[So] Source:Vojnosanit Pregl;73(11):1044-9, 2016 Nov.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Background/Aim: Some studies suggest the benefit of applying different probiotic strains in combination with antibiotics in the eradication of Helicobacter pylori (H. pylori) infection. The aim of this study was to evaluate the effect of co-administration of multiple probiotic strains with triple H. pylori eradication therapy.This prospective study included 167 patients with dyspeptic symptoms and chronic gastritis who were diagnosed with H. pylori infection and randomized into two groups. The group I of 77 patients underwent triple eradication therapy, for 7 days, with lansoprazole, 2 × 30 mg half an hour before the meal, amoxicillin 2 × 1.000 mg per 12 hours and clarithromycin 2 × 500 mg per 12 hours. After the 7th day of the therapy, lansoprazole continued at a dose of 30 mg for half an hour before breakfast for 4 weeks. The group II of 90 patients received the same treatment as the patients of the group I, with the addition of the probiotic cultures in the form of a capsule comprising Lactobacillus Rosell-52, Lactobacillus Rosell-11, Bifidobacterium Rosell-1755 and Saccharomyces boulardii, since the beginning of eradication for 4 weeks. Eradication of H. pylori infection control was performed 8 weeks after the therapy by rapid urease test and histopathologic evaluation of endoscopic biopsies or by stool antigen test for H. pylori.Eradication of H. pylori infection was achieved in 93.3% of the patients who received probiotics with eradication therapy and in 81.8% of patients who were only on eradication therapy without probiotics. The difference in eradication success was statistically significant, (p < 0.05). The incidence of adverse effects of eradication therapy was higher in the group of patients who were not on probiotic (28.6%) than in the group that received probiotic (17.7%), but the difference was not statistically significant.Multiple probiotic strains addition to triple eradication therapy of H. pylori achieves a significantly better eradication success, with fewer side effects of antibiotics.
[Mh] Termos MeSH primário: Amoxicilina/uso terapêutico
Antibacterianos/uso terapêutico
Claritromicina/uso terapêutico
Gastrite/tratamento farmacológico
Infecções por Helicobacter/tratamento farmacológico
Helicobacter pylori/efeitos dos fármacos
Lansoprazol/uso terapêutico
Probióticos/uso terapêutico
Inibidores da Bomba de Prótons/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Amoxicilina/efeitos adversos
Antibacterianos/efeitos adversos
Biópsia
Doença Crônica
Claritromicina/efeitos adversos
Quimioterapia Combinada
Feminino
Gastrite/diagnóstico
Gastrite/microbiologia
Gastroscopia
Infecções por Helicobacter/diagnóstico
Infecções por Helicobacter/microbiologia
Helicobacter pylori/patogenicidade
Seres Humanos
Lansoprazol/efeitos adversos
Masculino
Meia-Idade
Probióticos/efeitos adversos
Estudos Prospectivos
Inibidores da Bomba de Prótons/efeitos adversos
Sérvia
Fatores de Tempo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); 804826J2HU (Amoxicillin); H1250JIK0A (Clarithromycin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150415127G


  5 / 15186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241848
[Au] Autor:Libânio D; Dinis-Ribeiro M
[Ad] Endereço:Gastroenterology Department, Instituto Português de Oncologia do Porto, Porto, Portugal; MEDCIDS-Departamento Medicina da Comunidade, Informação e Decisão em Saúde, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
[Ti] Título:Gastroscopy and gastric cancer-related mortality: Time to change recommendations regarding screening?
[So] Source:Gastrointest Endosc;87(1):128-130, 2018 01.
[Is] ISSN:1097-6779
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Gastroscopia
Neoplasias Gástricas
[Mh] Termos MeSH secundário: Detecção Precoce de Câncer
Seres Humanos
Programas de Rastreamento
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  6 / 15186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384895
[Au] Autor:Yang MX; Zhao ZH; Yang JF; Chen B; Shen XZ; Wei JG; Wang BY
[Ad] Endereço:Department of Radiology.
[Ti] Título:Imaging findings of gastric plexiform fibromyxoma with a cystic change: A case report and review of literature.
[So] Source:Medicine (Baltimore);96(52):e8967, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Plexiform fibromyxoma (PF) is an extremely rare mesenchymal tumor of the stomach, and its radiological findings have not been well described. Here, we analyzed the imaging features of a case of PF. To our knowledge, this is a rare reported case with a remarkable cystic change in the imaging literature. PATIENT CONCERNS: A previously healthy 50-year-old woman presented with a 1-day history of abdominal pain. Then, she underwent computed tomography (CT) and magnetic resonance imaging (MRI). A cystic-solid well-circumscribed extraluminal mass was located in the posterior wall of the gastric upper body. The solid portion appeared as heterogeneous attenuation/intensity with progressive enhancement while the cystic region had no enhancement. DIAGNOSES: The potential for malignancy could not be excluded. INTERVENTIONS: Laparoscopic partial gastric resection was performed. OUTCOMES: Based on pathological findings, a diagnosis of PF was made. The patient was alive without any recurrence or metastasis of the tumor after 2 years of follow-up. LESSONS: As far as we know, a gastric PF with a remarkable cystic change has never been reported. Additionally, the tumor exhibited a progressive enhancement pattern which is a characteristic radiographic feature in our case. Our report may help increase the awareness of this rare but important new disease entity.
[Mh] Termos MeSH primário: Fibroma/diagnóstico por imagem
Neoplasias Gástricas/diagnóstico por imagem
[Mh] Termos MeSH secundário: Feminino
Fibroma/patologia
Fibroma/cirurgia
Gastroscopia
Seres Humanos
Imagem por Ressonância Magnética
Meia-Idade
Neoplasias Gástricas/patologia
Neoplasias Gástricas/cirurgia
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008967


  7 / 15186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29210540
[Au] Autor:Komori K; Nakamura K; Ihara E; Iwasa T; Hirahashi M; Oda Y; Takayanagi R
[Ti] Título:Endoscopic Submucosal Dissection is Feasible for Very Elderly Patients with Early Gastric Cancer : Comparison of Short-Term and Long-Term Outcomes in Very Elderly and Non-Elderly Patients.
[So] Source:Fukuoka Igaku Zasshi;107(4):72-81, 2016 Apr.
[Is] ISSN:0016-254X
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Background/Aims: Endoscopic submucosal dissection (ESD) has become a standard procedure for the resection of early gastric cancer (EGC). However, the feasibility of ESD for very elderly patients, aged ≥ 80 years, has not been determined. Methodology: The study population included 67 non-elderly (NE) patients aged ≤ 65 years (80 lesions) and 22 very elderly (VE) patients ≥ 80 years (26 lesions) with EGC who underwent ESD and met the criteria for absolute or expanded indications. Eighteen patients (18 lesions) who underwent ESD but did not meet the criteria for absolute and expanded indications were defined as the outside the indications (OI) group. Results: En bloc and complete resection rates were excellent in both the VE and NE groups, without differing significantly. Although the rates of ischemic heart disease and antithrombotic agent use were higher in the VE than in the NE group, procedure-related complication rates did not differ significantly. Of the seven very elderly patients in the OI group, two underwent additional gastrectomy, and the other five were followed-up without surgery. No patient in any group experienced local recurrence, metastasis or disease-specific death. Conclusions: Short- and long-term outcomes of ESD for VE patients with EGC were favorable and did not differ significantly from outcomes in NE patients. ESD may therefore be a good therapeutic option for both VE and NE patients with EGC.
[Mh] Termos MeSH primário: Mucosa Gástrica/cirurgia
Gastroscopia
Neoplasias Gástricas/cirurgia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Estudos de Viabilidade
Feminino
Seres Humanos
Masculino
Meia-Idade
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE


  8 / 15186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29223168
[Au] Autor:Nonaka H; Onishi H; Ozaki M; Kuriyama K; Komiyama T; Saito R
[Ad] Endereço:Department of Radiology, University of Yamanashi, 1110 Shimokato, Chuo City, Yamanashi, 409-3898, Japan. hnonaka@yamanashi.ac.jp.
[Ti] Título:Serious gastric perforation after second stereotactic body radiotherapy for peripheral lung cancer that recurred after initial stereotactic body radiotherapy: a case report.
[So] Source:J Med Case Rep;11(1):343, 2017 Dec 10.
[Is] ISSN:1752-1947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In recent reports, re-irradiation with stereotactic body radiotherapy for lung tumors in patients previously treated with thoracic radiation therapy resulted in several serious toxicities. Serious non-lung toxicities were observed mostly in patients with central tumors, but we experienced a case of fatal gastric perforation after a second stereotactic body radiotherapy in a patient with a peripheral lung tumor. CASE PRESENTATION: An 83-year-old Asian man was diagnosed with T2N0M0 lung cancer in the form of squamous cell carcinoma in the lower lobe of his left lung. He was treated with stereotactic body radiotherapy of 40 Gy in 4 fractions and the tumor decreased in size in partial response. The local tumor recurred 8 months after the first stereotactic body radiotherapy, and he was re-irradiated with a second stereotactic body radiotherapy of 50 Gy in 4 fractions. A Sengstaken-Blakemore tube was inserted below his diaphragm by laparoscopic surgery before the second stereotactic body radiotherapy in order to reduce the stomach dose by keeping his stomach apart from the tumor. Two months after the second stereotactic body radiotherapy, he developed fatal gastric perforation and gastropleural fistula penetrating his diaphragm. CONCLUSIONS: To the best of our knowledge, this is the first report about a gastric perforation after stereotactic body radiotherapy for lung tumors and it warns of serious complication of stereotactic body radiotherapy in not only centrally located but also peripherally located tumors like in this case.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/radioterapia
Fístula Gástrica/diagnóstico
Neoplasias Pulmonares/radioterapia
Recidiva Local de Neoplasia/radioterapia
Doenças Pleurais/diagnóstico
Lesões por Radiação/diagnóstico
Radiocirurgia/efeitos adversos
Gastropatias/diagnóstico
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Evolução Fatal
Gastroscopia
Seres Humanos
Masculino
Retratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171211
[St] Status:MEDLINE
[do] DOI:10.1186/s13256-017-1504-z


  9 / 15186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310354
[Au] Autor:Chu Y; Guo Q; Wu D
[Ad] Endereço:Department of Surgery, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, P.R. China.
[Ti] Título:Mesenteric fibromatosis after resection for gastrointestinal stromal tumor of stomach: A case report.
[So] Source:Medicine (Baltimore);96(48):e8792, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Gastrointestinal stromal tumor and mesenteric fibromatosis are rare mesenchymal tumors. Coexistence of these two diseases is uncommon, with only a few anecdotal reports of individuals. PATIENT CONCERNS: Clinical data and treatment of a 43-year-old man with subsequent mesenteric fibromatosis from gastrointestinal stromal tumor are summarized. The Ethics Committee of The Second Affiliated Hospital, College of Medicine, Zhejiang University approved this study, and the patient provided written informed consent form. DIAGNOSES: The initial diagnosis of the recurrent mesenteric mass was recurrent gastrointestinal stromal tumor. INTERVENTIONS: The operation was performed as possible at the time when the mass was found after the first surgery. OUTCOMES: The diagnosis was revised as mesenteric fibromatosis according to the postoperative immunohistochemical staining. The postoperative condition was normal without adjuvant therapy and no recidivation has been found. LESSONS: The potential for the coexistence of gastrointestinal stromal tumor and mesenteric fibromatosis should always be considered.
[Mh] Termos MeSH primário: Fibromatose Abdominal/patologia
Tumores do Estroma Gastrointestinal/patologia
Neoplasias Primárias Múltiplas/patologia
[Mh] Termos MeSH secundário: Adulto
Diagnóstico por Imagem
Fibromatose Abdominal/diagnóstico
Fibromatose Abdominal/cirurgia
Tumores do Estroma Gastrointestinal/cirurgia
Gastroscopia
Seres Humanos
Imuno-Histoquímica
Masculino
Neoplasias Primárias Múltiplas/diagnóstico
Neoplasias Primárias Múltiplas/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008792


  10 / 15186 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245266
[Au] Autor:Gurzu S; Bara T; Bara TJ; Turcu M; Mardare CV; Jung I
[Ad] Endereço:aDepartment of PathologybDepartment of Pathology, Clinical County Emergency HospitalcDepartment of Surgery, University of Medicine and Pharmacy, Tirgu-Mures, Romania.
[Ti] Título:Gastric Burkitt lymphoma: A case report and literature review.
[So] Source:Medicine (Baltimore);96(49):e8954, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Burkitt lymphoma (BL) is an endemic tumor in Africa but rare sporadic cases are diagnosed in Europe. PATIENT CONCERNS: A 60-year-old woman was hospitalized with fulminant hematemesis and a history of recurring melena. DIAGNOSES: The upper gastrointestinal endoscopy revealed a tumor of the antrum. INTERVENTIONS: Emergency gastrectomy was performed. OUTCOMES: Gross findings revealed an ulcerated tumor with elevated margins and several perigastric and extragastric lymph nodes. Histological examination showed proliferation of atypical lymphocytes with a Ki67 index of 100%; they were marked by CD20, CD79a, bcl-6, and CD10 and were negative for CD3, CD5, CD23, TdT, bcl-2, and Cyclin D1. The tumor cells crossed the serosa and presented invasion of the lymph nodes. The patient died 10 days after surgery due to bronchopneumonia and acute renal failure. LESSONS: In our department, only one gastric BL was diagnosed in a 61 consecutive lymphomas of the gastrointestinal tract (1.64%). Less than 200 reports about gastric-BL have been published to date. This case highlights the difficulty of diagnosis of rare variants of aggressive gastric lymphomas in medium-income countries without screening programmes.
[Mh] Termos MeSH primário: Linfoma de Burkitt/diagnóstico
Linfoma de Burkitt/cirurgia
Neoplasias Gástricas/diagnóstico
Neoplasias Gástricas/cirurgia
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/análise
Linfoma de Burkitt/patologia
Emergências
Evolução Fatal
Feminino
Gastrectomia
Gastroscopia
Seres Humanos
Metástase Linfática
Meia-Idade
Neoplasias Gástricas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171225
[Lr] Data última revisão:
171225
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008954



página 1 de 1519 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde